GARDP calls for nominations for an individual linked to Civil Society Organizations (CSO) representing voices of communities and / or patient centred professional Board member
Terms of Reference
The Global Antibiotic Research and Development Partnership Board is seeking to enhance its competencies with the addition of a Board member with direct experience in engaging with patients and patient groups impacted by drug resistance infections and / or current, relevant civil society engagement, analysis and outlook in countries with a high burden of AMR.
GARDP is an independent, not-for-profit foundation registered under the Swiss Civil Code, administered by a Board of Directors (the Board). Board members are experts in their field and are chosen for their commitment to the public interest R&D, their technical competency, and their support of the mission of GARDP. The Board has powers over all matters pertaining to GARDP, notably, approving the overall policies and principles of GARDP, including those related to ethical considerations and fundraising strategies; approving project selection; and approving the annual work plan and budget.
Board members are selected from areas of expertise including (but not limited to) pharma/biotech research and development and related science, business development, clinical development, public health, fundraising, finance, legal, and global health communications and advocacy. The Board currently has 6 members. The Board is seeking to enhance its competencies with the addition of a Board member with linked to Civil Society Organisations (CSO) representing voices of communities and / or patient centred professional with experience in countries with a high burden of AMR. The experience should reinforce the Board in gaining:
– An independent voice able to support GARDP’s advocacy strategy and promote a strong social mission focus separate from both the individual state and market interests
– Patient and community experience with strong personal experience / interest on the need for new antibiotics
– A patient centred professional with medical experience in a variety of AMR realities (co-infections, high / low burden, community and hospital settings)
– Experience with CSO with public health knowledge and ability to link to multiple social realities
– Network connections especially in LMICs with regional and international connections
Board members serve a term of three years and serve in an honorary capacity. GARDP will reimburse reasonable expenses related to Board work, including travel expenses. The closing date for applications is 20 May 2022. To nominate someone or self-nominate, please fill in the nomination form and e-mail it to firstname.lastname@example.org.
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in 2016 to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children. GARDP is funded by the governments of Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom, as well as Médecins Sans Frontières and private foundations. www.gardp.org